Conditions: Akathisia, Drug-Induced Dyskinesia, Drug-Induced Parkinsonian Disorders
Keywords: Anti-Dyskinesia Agents Antipsychotic Agents
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 11
Healthy volunteers: no

Brief summary:
This study was designed to determine if preladenant (SCH 420814, MK-3814) can reduce drug-induced involuntary movements in participants with schizophrenia or schizoaffective disorder. Participants were to be evaluated for two 14-day treatment periods with a 3-week washout period between treatment periods. The primary outcome measure, Extrapyramidal Symptom Rating Score (ESRS), was to be evaluated frequently during the treatment periods.

Detailed description:

Arms:
arm 1: Participants received one preladenant 25 mg capsule twice daily (BID) for 14 days during the first treatment period and received one matching placebo capsule BID during the second treatment period. The 2 treatment periods were separated by a 3-week washout period. arm 2: Participants received one matching placebo capsule BID for 14 days during the first treatment period and received one preladenant 25 mg capsule during the second treatment period. The 2 treatment periods were separated by a 3-week washout period.

Interventions: intervention 1: Preladenant intervention 2: Placebo
Intervention descriptions: intervention 1: capsules intervention 2: capsules

Protocol document: